Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
BUSINESS
Takeda Files Japan NDA for Narcolepsy Drug Oveporexton
Takeda Pharmaceutical said on March 4 that it has filed a new drug application in Japan for oveporexton, an oral orexin receptor 2 (OX2R) selective agonist, for the treatment of narcolepsy type 1 (NT1). Designed to address the orexin deficiency…
To read the full story
Related Article
- Takeda’s Oveporexton, Rhythm’s Imcivree Up for Japan Panel Review Aug. 3
July 21, 2026
- Takeda Reports Additional Benefits for Narcolepsy Drug Oveporexton
June 17, 2026
- Takeda’s Narcolepsy Drug Accepted for US FDA Review
February 12, 2026
- Takeda’s OX2R Agonist Makes Mark in PIII NT1 Trials, US Filing Planned in FY2025
July 15, 2025
- TAK-861 Hits Main Goal in PIIb Trial, PIII Set to Begin in 1H FY2024: Takeda
June 6, 2024
BUSINESS
- Chugai Forms Strategic Investment Unit to Deepen Innovation Push; Record Japan Filings Eyed
July 27, 2026
- Chugai Notches Strong H1 Growth on Key Products, Roche Exports
July 27, 2026
- Meiji’s Hiyasta Hits PIII Goal in Advanced Melanoma
July 27, 2026
- China First to Approve Takeda’s Oveporexton for Narcolepsy
July 24, 2026
- FRONTEO Expects First US User of KIBIT AI Engine This Year: CEO
July 24, 2026
Japan’s pharmaceutical industry could be on the verge of gaining a stronger voice in the Central Social Insurance Medical Council…
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…